Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01891136 · ClinicalTrials.gov registry record · Early Phase 1
Oral Peanut Immunotherapy for Peanut Allergic Patients
A Early Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 36
- Enrollment target
NCT01891136 is a Early Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 36 participants.
The verdict
NCT01891136, a Early Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a study to determine if peanut oral immunotherapy (OIT) would desensitize or tolerize peanut allergic patients to peanuts in order prevent peanut allergic reactions.
Interventions
- DRUG Peanut protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-04 |
| Est. Completion | 2014-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01891136
The ClinicalTrials.gov registry entry for NCT01891136 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peanut protein is the first listed.
NCT01891136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01891136 about?
NCT01891136 is a clinical study titled "Oral Peanut Immunotherapy for Peanut Allergic Patients". This is a study to determine if peanut oral immunotherapy (OIT) would desensitize or tolerize peanut allergic patients to peanuts in order prevent peanut allergic reactions.
What is the current status of trial NCT01891136?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 36 participants. The study started on 2004-04. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01891136?
The interventions under investigation include: Peanut protein (DRUG).
Who is sponsoring clinical trial NCT01891136?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.